Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm

Vaxcyte CEO Grant Pickering sold 6,289 shares (~$384,900) to cover tax withholding on vesting restricted stock units, retaining 447,000 direct shares. The clinical-stage biotech company, up 95% over the past year, is awaiting pivotal Phase 3 trial data for VAX-31 in Q4 2026. With $2.5 billion in cash but burning $284.3 million quarterly, the company's future hinges on successful trial results.